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Ferrocenyl-Coupled N-Heterocyclic Carbene Complexes of 
Gold(I): a Successful Approach to Multinuclear Anticancer Drugs 
Julienne K. Muenzner,[a] Bernhard Biersack,[a] Alexander Albrecht,[a] Tobias Rehm,[a] Ulrike Lacher,[a] 
Wolfgang Milius,[b] Angela Casini,[c,d] Jing-Jing Zhang,[e] Ingo Ott,[e] Viktor Brabec,[f,g] Olga 
Stuchlikova,[f,g] Ion C. Andronache,[h] Leonard Kaps,[i] Detlef Schuppan,[i,j] and Rainer Schobert*[a] 
 
Abstract: Four gold(I) carbene complexes featuring 4-ferrocenyl 
substituted imidazol-2-ylidene ligands were investigated for 
antiproliferative and antivascular properties. They were active 
against a panel of seven cancer cell lines, including multidrug-
resistant ones, with low micromolar or nanomolar IC50 (72 h) values, 
according to their lipophilicity and cellular uptake. The delocalised 
lipophilic cationic complexes 8 and 10 acted by increasing the 
reactive oxygen species in two ways: via a genuine ferrocene effect 
and by inhibiting the thioredoxin reductase. Both complexes gave 
rise to a reorganization of the F-actin cytoskeleton in endothelial and 
melanoma cells, associated with a G1 phase cell cycle arrest and a 
retarded cell migration. They proved antiangiogenic in tube formation 
assays with endothelial cells and vascular-disruptive on real blood 
vessels in the chorioallantoic membrane of chicken eggs. 
Biscarbene complex 10 was also tolerated well by mice where it led 
to a volume reduction of xenograft tumors by up to 80%. 
Introduction 
A common strategy to improve the impact of metallodrugs is the 
optimization of their pharmacokinetic and pharmacodynamic 
properties.[1,2] A less frequent approach uses the decoration of 
bioactive metal fragments with ligands or shuttle groups that 
show some bioactivity or functionality of their own. In felicitous 
cases pleiotropic drugs result that not only retain the individual 
properties of metal and ligand but also exhibit some new 
effects.[3–6] N-heterocyclic carbene (NHC) ligands are poor 
leaving groups and thus lend themselves ideally to the 
permanent introduction of modulatory substituents at their 
heterocycle.[3,6] Previously, we reported on gold(I) mono- and 
biscarbene complexes (1, 2) with imidazole ligands that had 
been modeled on the natural antivascular agent combretastatin 
A-4 (CA-4) (Figure1).[7–9] They proved highly cytotoxic and 
efficacious against cancer cell lines of various entities with IC50 
values in the low micromolar or even submicromolar range. 
Despite their different molecular mechanism of action when 
compared to CA-4, they also retained a significant antivascular 
activity both in vitro and in vivo.  
Figure 1. The natural vascular-disruptive agent combretastatin A-4 (CA-4) and 
its analogous gold(I) NHC complexes 1 and 2. 
Since gold NHC complexes had been reported to interfere with 
the redox machinery of cells, e.g., the mitochondria or specific 
antioxidative enzymes such as thioredoxin reductase (TrxR),[3,5,6] 
we intended to attach an electronically coupled, redox-active 
ferrocenyl residue to the NHC ligand of gold(I) complexes. The 
concept of enhancing the activity or selectivity of anticancer 
metallodrugs by introduction of further metal centers is not 
new.[10–13] Ferrocene is known to activate lymphocytes and to 
exert distinct antitumor effects which are associated with the 
production and regulation of reactive oxygen species (ROS) and 
the oxidation of Ras proteins at cysteine sites.[14] A host of 
antitumoral ferrocene derivatives have been published, including 
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conjugates with peptides, benzotriazoles, nucleobases, estrogen 
receptor modulators, and fungal cytotoxins like illudin M.[15–19] 
There are also reports on gold complexes conjugated to 
ferrocene with distinct anticancer activities against various 
cancer cell lines.[11,20] In the present paper, we report on the 
synthesis and structure-dependent anticancer properties in vitro 
and in vivo of new carbene complexes of gold(I) featuring 
ferrocenyl-coupled imidazol-2-ylidene ligands. 
Results and Discussion 
Chemistry 
The N-alkyl-5-ferrocenyl-4-phenyl-imidazoles 4 were obtained 
via a Van-Leusen imidazole synthesis starting from ferrocenyl 
carboxaldehyde and the TosMIC reagent 3 (Scheme 1). 
Alkylation of complexes 4 with iodomethane or iodoethane 
afforded the corresponding imidazolium salts 5, which were 
treated with silver(I) oxide to give the silver(I) carbene 
complexes 6. Their transmetallation with chlorido(dimethyl-
sulfide)gold(I) gave the chlorido(NHC)gold(I) complexes 7. The 
cationic phosphano gold complex 8 was obtained from the 
reaction of 7b with PPh3 and NaBF4.
[21]  
Scheme 1. Syntheses of gold(I) NHC complexes 7, 8, and 10. Reagents and 
conditions: a) ferrocenyl carboxaldehyde, 33% MeNH2/EtOH or 2M EtNH2/THF, 
AcOH, EtOH, reflux, 2 h, then 3, K2CO3, EtOH, reflux, 3 h; b) MeI or EtI, MeCN, 
80 °C, 16 h; c) Ag2O, CH2Cl2, r.t., 16 h; d) Cl(Me2S)Au, CH2Cl2, r.t., 16 h; e) 7b, 
NaBF4, PPh3, acetone, r.t., 1 h; f) NaBF4, acetone, r.t., 16 h, 100%; g) Ag2O, 
CH2Cl2, r.t., 5 h, then Cl(Me2S)Au (0.5 equiv.), CH2Cl2, r.t., 16 h. 
The cationic biscarbene complex 10 was prepared from 
imidazolium iodide 5b which had its counter anion substituted for 
BF4 to give complex 9. This was converted with Ag2O to the 
corresponding silver carbene complex which was not isolated 
but transmetallated with 0.5 equivalents of Cl(Me2S)Au to afford 
complex 10 (Scheme 1, bottom row). Crystals of complex 10 
suitable for X-ray diffraction analyses were grown by slow 
infusion of ether into a saturated CH2Cl2 solution at 4 °C (Figure 
2). The cyclic voltammograms of the new complexes showed an 
anodic shift of the redox potential E1/2 relative to ferrocene, e.g. 
by 145 mV in the case of neutral 7b (cf. Supporting Information). 
Figure 2. Molecular structure of complex 10 as thermal ellipsoid 
representation at 50% probability level (H atoms omitted). Selected bond 
lengths [Å] and angles [°]: Au-C1 2.02, C1-N1 1.35(1), N1-C4 1.38(1), C4-C5 
1.44(1), C5-Fe 2.092(8), C1-Au-C1 180.0, Au-C1-N1 127.0, N1-C1-N2 
105.8(7), C5-C4-N1 126.8(8). 
Antiproliferative activity in vitro 
The effect of complexes 7, 8, and 10 on the growth of cancer 
cells was evaluated in proliferation assays using 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) that is 
reduced to a violet formazan in viable cells.[22] To assess 
potential selectivities for cancer over non-malignant cells, 
CCD18-Co colorectal myofibroblasts were included (Table 1). 
The N-methylated monocarbene complex 7a was 
antiproliferative with IC50 values mostly in the lower micromolar 
range (IC50 (72 h) = ca. 7–20 !M), while its N-ethyl analog 7b 
was significantly more active (IC50 (72 h) = ca. 0.2–4 !M). 
Moreover, we found that replacing the chlorido ligand by a 
triphenylphosphane or a second NHC ligand, as in the cationic 
complexes 8 and 10, further enhanced the antiproliferative effect, 
giving rise to IC50 values in the lower submicromolar range with 
complex 10 being slightly more active than complex 8. This 
trend of increasing cytotoxicities when substituting a chlorido for 
a phosphane or NHC ligand has previously been observed for 
NHC gold(I) complexes of the benzimidazol-2-ylidene type by 
Rubbiani et al.[23] Interestingly, all complexes 7, 8, and 10 were 
active also against multidrug-resistant tumor cell lines such as 
HT-29 colon,[24,25] MCF-7/Topo breast,26,27 and – with the 
exception of complex 7a – KB-V1/Vbl cervix carcinomas. Pre-
treatment of KB-V1/Vbl cells which overexpress P-glycoprotein 
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1[28-30] with verapamil, an inhibitor of this efflux transporter, for 24 
h improved the effect of all complexes by a factor of 4 to 35. This 
suggests that they are themselves substrates of P-gp, like the 
CA-4 derived biscarbene complexes 2.[9] The complexes 7, 8, 
and 10 also strongly inhibited the growth of human umbilical vein 
endothelial cells (HUVEC), which is a hint at a potential 
antivascular activity. In contrast, the non-malignant CCD18-Co 
fibroblasts were affected only at higher complex concentrations.  
 
Table 1. Inhibitory concentrations[a] IC50 [µM] of complexes 7, 8, and 10 when 
applied to human cancer cells and non-malignant cells. 
Cell line
[b] 7a 7b 8 10 
518A2 11.3 ± 0.3 1.3 ± 0.1 0.20 ± 0.03 0.19 ± 0.02 
Panc-1 6.7 ± 0.3 0.62 ± 0.01 0.14 ± 0.02 0.09 ± 0.00 
MCF-7/Topo 7.1 ± 0.1 0.71 ± 0.02 0.60 ± 0.01 0.11 ± 0.00 
KB-V1/Vbl > 50 13.3 ± 0.1 1.6 ± 0.4 1.5 ± 0.1 
KB-V1/Vbl 
+verapamil 
2.0 ± 0.6 0.38 ± 0.12 0.40 ± 0.08 0.11 ± 0.01 
HCT-116 11.1 ± 0.3 0.21 ± 0.08 0.09 ± 0.01 0.06 ± 0.00 
HT-29 10.8 ± 0.4 0.30 ± 0.08 0.16 ± 0.02 0.13 ± 0.01 
DLD-1 19.5 ± 1.0 4.2 ± 1.4 1.2 ± 0.5 0.30 ± 0.11 
HUVEC 12.0 ± 1.5 0.68 ± 0.07 0.77 ± 0.17 0.26 ± 0.04 
CCD-18Co > 50 15.0 ± 0.9 8.9 ± 0.3 2.8 ± 0.1 
[a] Values are derived from dose-response curves obtained by measuring 
the percentage of viable cells relative to untreated controls after 72 h of 
incubation using MTT assays. Values represent means of four experiments ± 
standard deviations. [b] Human cancer cell lines: 518A2 melanoma, Panc-1 
pancreatic ductular adenocarcinoma, MCF-7/Topo breast adenocarcinoma, 
KB-V1/Vbl cervix carcinoma (optionally pretreated with 24 !M verapamil for 
24 h), HCT-116 colon carcinoma, HT-29 and DLD-1 colorectal 
adenocarcinoma; human non-malignant cells: HUVEC primary human 
umbilical vein endothelial cells and CCD-18Co human colon fibroblasts. 
Cellular accumulation and lipophilicity 
The activity of drugs depends on their intracellular accumulation. 
The uptake of complexes 7, 8, and 10 by HCT-116 cells that had 
been exposed to 0.5 !M concentrations of the compounds for 24 
h, was measured by ICP-MS analysis of their iron content (Table 
2). Additionally, the coefficient log P for their partition between 1-
octanol and water was determined in order to identify 
correlations between lipophilicity, cellular uptake and 
cytotoxicity.[31,32] They displayed a largely hydrophilic character 
with negative log P values that correlate with their respective 
cellular accumulation. The most hydrophilic complex 7a showed 
the least uptake. Its more lipophilic N-ethyl analog 7b was taken 
up to a greater extent. The cytotoxicities of the complexes 7 tie 
in nicely with their lipophilicities and accumulations. Complex 7b 
is active in HCT-116 cells with an IC50 value about 50 times 
lower than that of complex 7a. The cationic phosphane complex 
10 has a log P value near 0 and thus a greater lipophilicity than 
the neutral complexes 7. Consequently, it also showed the 
greatest accumulation in HCT-116 cells which fits in with its high 
cytotoxicity against this cancer cell line.  
 
Table 2. Cellular iron uptake from complexes 7, 8, and 10 in HCT-116 colon 
carcinoma cells and their log P (1-octanol/water) values. Cells were exposed 
to the test compounds (0.5 µM) for 24 h before analyzing the metal content. 
The log P values of the complexes were determined by the shake flask 
method. The results are expressed as means ± SD of three independent 
samples for each experiment.  
 7a 7b 8 10 
ng Fe / 
10
6
 cells 
3.06 ± 0.06 4.17 ± 0.04 3.15 ± 0.05 18.9 ± 1.6 
log P –1.71 ± 0.05 –0.07 ± 0.01 –1.30 ± 0.02 0.06 ± 0.00 
 
 
Effects on the cytoskeletal organization 
Like the CA-4 derived complexes 1 and 2,[7–9] the new ferrocenyl 
complexes did not interfere with the polymerization of tubulin or 
with the organization of microtubules in cells, but induced a 
distinct reorganization of the actin cytoskeleton in both 518A2 
melanoma cells and non-malignant HUVEC. For instance, when 
we visualized microtubules (not shown) and filamentous actin 
(F-actin) in these cells after treatment with 500 nM of 8 or 250 
nM of 10, we saw changes only in the organization of the latter 
(Figure 3). Both complexes led to the formation of sheaves of 
parallel actin fibers running across the entire cell bodies, in 
contrast to the cortical networks of actin observed in untreated 
control cells. The stress fiber formation was more pronounced in 
HUVEC than in the tumor cells, and more for complex 10 than 
for complex 8. 
 
Figure 3. Effects on the organization of F-actin in human vascular endothelial 
(HUVEC) and 518A2 melanoma cells. Both cell lines were treated with 500 nM 
of 8, 250 nM of 10, or DMF as vehicle control for 24 h. Scale bar - 50 !m. 
    
 
 
 
 
 
Effects on tumor cell cycle and migration 
The effects of complexes 8 and 10 on the cell cycle progression 
of 518A2 melanoma cells were analyzed by propidium iodide 
staining and flow cytometry (Figure 4A). Both complexes 
induced a significant accumulation of cells in the G1 phase, with 
complex 10 again being slightly more effective. The fractions of 
cells in S and G2/M phase were distinctly reduced while the sub-
G1 population of apoptotic cells rose slightly for the applied 
concentrations of complexes 8 (500 nM) and 10 (250 nM).  
Both, the reduced dynamics of the actin cytoskeleton and the 
marked G1 phase arrest diminished the motility and thus 
invasiveness of the melanoma cells.[33,34] In so-called wound 
healing assays the complexes 8 and 10 reduced their ability to 
close artificial wounds, i.e., scratches in cell monolayers when 
compared to untreated cells. While treatment of 518A2 cells with 
500 nM of complex 8 for 48 h reduced the wound healing to ca. 
70%, the biscarbene complex 10 was a more potent inhibitor of 
cell migration, reducing the wound healing to ca. 40% when 
applied at the same concentration (Figure 4B). 
 
Figure 4. A) Fractions of 518A2 melanoma cells in G1, S, and G2/M phase of 
the cell cycle, and apoptotic cells (sub-G1 population) upon treatment with 500 
nM of 8, 250 nM of 10, or vehicle for 24 h as obtained by flow cytometry after 
DNA staining with propidium iodide. Values represent means ± SD of three 
independent experiments. B) Inhibitory effects of complexes 8 and 10 
(500 nM) on the migration of 518A2 melanoma cells in wound healing assays. 
Values represent means ± SD of three experiments. 
Interference with the tumor cell redox poise  
The thioredoxin reductase (TrxR) is involved in maintaining the 
intracellular redox homeostasis and plays an important role in 
the regulation of cell proliferation and survival.[36,37] Its inhibition 
leads to an increase of reactive oxygen species (ROS) in cells, 
to an interference with mitochondrial functions, and eventually to 
apoptosis. Since TrxR had already been identified as an 
important target of gold(I) NHC complexes[3,5,6,38,39] we analyzed 
the cationic complexes 8 and 10 for a potential inhibition of 
isolated TrxR in vitro. The phosphane complex 8 proved a 
potent TrxR inhibitor with an EC50 = 0.6 ± 0.1 !M, while the 
biscarbene complex 10 was slightly less effective with an EC50 = 
1.5 ± 0.2 !M. A possible explanation for this difference is that 
triphenylphosphane is a better leaving group than an NHC 
ligand. This allows a faster binding interaction of the gold center 
of complex 8 with the selenocysteine residue in the active site of 
the TrxR. Recently, Rubbiani et al. reported a similar gradation 
of the TrxR inhibiting effects of phosphane vs. NHC substituted 
benzimidazolylidene gold(I) complexes.[23,38] The different 
potential of complexes 7b, 8, and 10 to inhibit the seleno-
enzyme TrxR was also assessed by a model reaction with in situ 
generated seleno-L-cysteine and MS analytics of the resulting 
adducts as previously described.[40,41] We found that complexes 
7b and 8 readily formed mono selenol adducts with substitution 
of the chloro or phosphane ligands, respectively, while the 
biscarbene complex 10 did not (cf. Supporting Information). 
Additionally, we tested them for inhibition of purified poly(ADP-
ribose) polymerase 1 (PARP-1), an enzyme that plays an 
important role during the initiation of DNA repair and in drug 
resistance mechanisms of cancer cells. PARP-1 has also been 
identified, recently, as a target for gold complexes as well as for 
heteronuclear iron-gold complexes.[11,42,43] Complex 10 was a 
more effective inhibitor of PARP-1 (EC50 = 1.0 ± 0.4 !M) than 
complex 8 (EC50 = 2.0 ± 0.3 !M). Previously, Lease et al. 
reported a trinuclear Fe-Au(III) complex that also inhibited 
PARP-1 with an EC50 of ca. 1 !M.[11] It should be noted, though, 
that other Au(I) and Au(III) complexes with N-donor and 
phosphane ligands are known that inhibit PARP-1 with EC50 
values in the nanomolar range.[42,43]  
Reactive oxygen species (ROS) are associated with the mode of 
action of ferrocene derivatives. There are numerous studies of 
the correlation between ROS production and antiproliferative 
effects of ferrocenes, including heteronuclear ferrocene–gold 
complexes.[14,20,44] The effect of complexes 8 and 10 on the ROS 
levels in 518A2 melanoma cells was now investigated by the 
nitroblue tetrazolium chloride (NBT) test (Figure 5A). When 
applied at lower concentrations, only complex 10 led to an 
increase of ROS. At a concentration of 500 nM it caused a 1.6 
times higher level of ROS when compared with untreated control 
cells, while complex 8 had virtually no effect at this concentration. 
However, at the highest applied concentration of 1 !M both 
complexes raised the ROS levels equally to ca. 180 % relative to 
controls. There seem to be at least two ROS increasing effects: 
a genuine ferrocene effect, which explains the higher ROS 
levels initiated by the bisferrocenyl complex 10 at lower 
concentrations, and the rise of ROS levels brought about via 
TrxR inhibition38,45,46 which is more pronounced for the 
monoferrocenyl complex 8 and which overrides the stronger 
ferrocene effect by complex 10 at higher concentrations.  
 
Figure 5. A) ROS levels in 518A2 melanoma cells as determined by NBT 
assays. Cells were treated with 250 nM, 500 nM, or 1 !M of complexes 8 and 
10 or respective amounts of DMF (controls) for 24 h. Values represent means 
    
 
 
 
 
 
± SD of two independent experiments in triplicate. B) Effects on the 
mitochondrial membrane potential in 518A2 melanoma cells as observed in 
JC-1 assays with cells treated as above. Values represent means ± SD of two 
independent experiments in triplicate. 
The mitochondrial membrane potential "#m is known to be 
affected by the inhibition of TrxR by gold(I) complexes.[45–48] Both 
complexes 8 and 10 are delocalized lipophilic cations (DLC), 
which are known to accumulate in mitochondria, disturb 
essential functions of these, and lead to the loss of "#m, 
eventually inducing the intrinsic pathway of apoptosis.[49–51] The 
effects of complexes 8 and 10 on the "#m in 518A2 melanoma 
cells were evaluated by a JC-1 assay (Figure 5B). Both 
complexes initiated a concentration-dependent reduction in the 
fraction of cells with an intact "#m. Despite its less pronounced 
TrxR inhibition the biscarbene complex 10, when applied at 1 
!M, reduced the fraction of cells with unaltered "#m to ca. 45%, 
and thus more strongly than complex 8 which left ca. 65% of 
mitochondria with intact "#m. A possible explanation lies in the 
higher lipophilicity of complex 10 which facilitates its uptake into 
mitochondria.[52]  
 
Antivascular effects  
Tube formation assay: To assess the antiangiogenic activity of 
complexes 8 and 10 we performed in vitro tube formation assays 
which are based on the ability of vascular endothelial cells to 
form interconnected networks of capillary-like structures when 
grown on an extracellular membrane matrix support such as 
matrigel.[53] For this, HUVEC were seeded on matrigel, treated 
with various concentrations of the test compounds and the 
effects on the formation of tubular networks were documented 
after 24 h of incubation. Figure 6 shows the results. While 
control cells had built up highly organized networks of capillary-
like structures, both complexes 8 and 10 strongly impaired the 
formation of such tubular structures when applied at 
concentrations as low as 100 nM.  
 
Figure 6. Inhibitory effects of complexes 8 and 10 (each 100 nM) on the 
formation of organized tubular networks by HUVEC seeded on matrigel after 
24 h of incubation. 
The chorioallantoic membrane (CAM) of fertilized chicken eggs 
is highly vascularized and serves as the respiratory system.[54,55] 
It can be used as a simple in vivo model system to study the 
antiangiogenic or vascular-disruptive effects of new drug 
candidates.[9,54–56] Figure 7 depicts the antivascular effects of 
complexes 8 and 10 in comparison to the normal development 
of blood vessels in the CAM. After 6 h of incubation complex 8 
had destroyed nearly all smaller capillaries while complex 10 
had affected even bigger vessels and had induced hemorrhages. 
These effects were quantified by a vessel area analysis based 
on a fractal analysis as described previously.[9,57] The area of 
blood vessels was decreased to 47 ± 6% by complex 8, and to 
27 ± 1% by complex 10. After 24 h of incubation with complex 8 
the vasculature within the treated area had recovered and the 
sprouting of new blood vessels was detected. In contrast, 
treatment with complex 10 for 24 h led to a further destruction of 
the vasculature.  
 
Figure 7. Antivascular effects of complexes 8 and 10 on the chorioallantoic 
membrane of fertilized chicken eggs. Images were taken 6 h and 24 h after 
application of the test compounds (2.5 nmol) on day 7 post fertilization and are 
representative of at least three independent assays. 
In vivo mouse xenograft model  
The antitumoral activity of biscarbene complex 10 was further 
assessed in vivo using a Balb/c mouse xenograft model of 
invasive B16-F10 melanoma. The results are shown in Figure 8. 
Complex 10 was administered intraperitoneally to the mice twice 
on two consecutive days (each time 7.5 mg/kg body weight on 
days 1, 2, 7, and 8). This induced a considerable reduction in 
tumor volumes to 18-48% of the initial size after twelve days 
while the volumes of untreated B16-F10 tumors increased by 
1.6- to 1.9-fold. The weight of the mice remained nearly the 
same as at the beginning of the experiment. Thus, it can be 
concluded from this preliminary study that complex 10 exhibits a 
significant in vivo antitumor activity against this type of highly 
metastatic melanoma while being tolerated very well by the mice.  
 
    
 
 
 
 
 
Figure 8. Antitumoral activity of complex 10 in mouse xenografts of the highly 
metastatic B16-F10 melanoma cell line. Shown are the relative tumor 
responses following a repeated application of DMSO (control) or complex 10 
on two concecutive days (i.p. injections of 7.5 mg/kg body weight on days 1, 2, 
7, and 8: black arrows). Data are means ± SD of the tumors implanted in both 
flanks of each mouse. 
Conclusions 
The ferrocenyl substituted NHC gold(I) complexes 7a, 7b, 8, and 
10 showed activity against various tumor cell entities with IC50 
values in the lower micromolar or even submicromolar range. In 
xenografted mice complex 10 led to significant reductions of the 
tumor volumes while being tolerated well by the animals. The 
cytotoxicity of the complexes is correlated with their cellular 
uptake, which is dependent on their lipophilicity. The mechanism 
of action of complexes 8 and 10 was studied in detail. They 
induced a distinct reorganization of the F-actin cytoskeleton in 
human vascular endothelial and melanoma cells, which was 
associated with an accumulation of the cells in the G1 phase of 
the cell cycle leading to a significant antimigratory effect. 
Moreover, complexes 8 and 10 are potent inhibitors of the redox 
enzyme TrxR with complex 8 being about 2.5 times more 
effective than complex 10. This is in line with findings by 
Rubbiani et al. for similar gold(I) NHC complexes and is most 
likely due to the lower stability of complex 8 leading to a higher 
reactivity toward nucleophiles present in the active site of the 
TrxR enzyme.[23,38] Our results indicate that not only the 
inhibition of TrxR but also the presence of the ROS 
regulating/producing ferrocene moieties in complexes 8 and 10 
are responsible for the observed increase in the cellular ROS 
levels. The accumulation of ROS in the investigated melanoma 
cells was also associated with a decrease in the mitochondrial 
membrane potential. Such antimitochondrial effects are typical 
of agents that alter the intracellular redox homeostasis.[45–48] The 
complexes 8 and 10 also showed distinct antivascular effects, 
such as an inhibition of the formation of vessel-like structures by 
HUVEC in vitro, and a disruption of the vasculature in the CAM 
of fertilized chicken eggs. This pleiotropic spectrum of anticancer 
effects in vitro and in vivo makes these new heteronuclear NHC 
complexes promising drug candidates. We will now study their 
effects on cancer-relevant signal transduction pathways by 
proteomic techniques known to be applicable to gold complexes 
such as ELISA microarray analyses[58,59] or two-dimensional 
difference gel electrophoresis.[60] 
Experimental Section 
General: Melting points are uncorrected; IR spectra were recorded on an 
FT-IR spectrophotometer with ATR sampling unit; NMR spectra were run 
on 300 and 500 MHz spectrometers; chemical shifts are given in ppm ($) 
downfield from tetramethylsilane as internal standard for 1H and 13C; 
mass spectra: direct inlet, EI, 70 eV; HRMS: UPLC/Orbitrap MS system 
in ESI mode; microanalyses: Vario EL III elemental analyser. All tested 
compounds are > 98% pure by elemental analysis and HPLC. For in vitro 
tests stock solutions of the complexes in DMF, stable for months, were 
prepared.  
Chemistry. 1-Methyl-5-ferrocenyl-4-phenylimidazole (4a): Ferrocenyl 
carboxaldehyde (90 mg, 0.42 mmol) was dissolved in ethanol (15 mL), 
treated with 33% MeNH2/EtOH (260 !L, 2.10 mmol) and acetic acid (150 
!L, 2.63 mmol), and heated for 2 h under reflux. TosMIC reagent 3 (120 
mg, 0.44 mmol) and K2CO3 (500 mg, 3.62 mmol) were added and the 
reaction mixture was stirred for 6 h under reflux. The volatiles were 
evaporated and the residue was suspended in ethyl acetate, washed with 
water, dried over Na2SO4, filtered, and the filtrate was concentrated in 
vacuum. The residue was purified by column chromatography (silica gel 
60). Yield: 75 mg (0.32 mmol, 76%); orange-brown solid; Rf=0.44 (ethyl 
acetate); 1H NMR (300 MHz, CDCl3) !=3.93 (s, 3H), 4.0–4.1 (m, 5H), 
4.2–4.3 (m, 4H), 7.2–7.4 (m, 3H), 7.4–7.5 ppm (m, 3H); 13C NMR (75.5 
MHz, CDCl3) !=32.8, 68.1, 68.7, 69.0, 75.3, 126.6, 127.8, 128.7, 130.6, 
135.6, 137.8, 140.2 ppm; "max/cm-1: 3086, 2923, 1603, 1511, 1442, 1415, 
1392, 1374, 1322, 1285, 1254, 1204, 1156, 1103, 1088, 1070, 1031, 998, 
955, 915, 889, 867, 834, 824, 811, 774, 752, 719, 697, 663; MS (70eV): 
m/z (%) 342 (100) [M+], 277 (25), 234 (26), 220 (75), 165 (42). 
1-Ethyl-5-ferrocenyl-4-phenylimidazole (4b): Ferrocenyl carboxaldehy-
de (90 mg, 0.42 mmol) was dissolved in ethanol (15 mL), treated with 2M 
EtNH2/THF (1.05 mL, 2.10 mmol) and acetic acid (150 !L, 2.63 mmol), 
and heated for 2 h under reflux. Compound 3 (120 mg, 0.44 mmol) and 
K2CO3 (500 mg, 3.62 mmol) were added and the reaction mixture was 
heated for 6 h under reflux. The solvent was evaporated and the residue 
was suspended in ethyl acetate, washed with water, dried over Na2SO4, 
filtered, and the filtrate was concentrated in vacuum. The residue was 
purified by column chromatography (silica gel 60). Yield: 100 mg (0.28 
mmol, 67%); orange-brown solid; Rf=0.77 (ethyl acetate/methanol 9:1); 
1H NMR (300 MHz, CDCl3) !=1.51 (t, J = 7.3 Hz, 3H), 3.9–4.0 (m, 5H), 
4.2–4.3 (m, 4H), 4.43 (q, J = 7.3 Hz, 2H), 7.1–7.3 (m, 3H), 7.4–7.5 (m, 
2H), 7.57 (s, 1H); 13C NMR (75.5 MHz, CDCl3) !=16.9, 39.8, 68.1, 68.9, 
69.0, 75.3, 124.2, 126.5, 127.7, 128.7, 130.7, 135.6, 136.1, 140.0; 
"max/cm-1: 3089, 2974, 2933, 1602, 1506, 1442, 1411, 1378, 1347, 1250, 
1199, 1105, 1070, 1029, 1000, 948, 912, 875, 819, 771, 721, 697, 662; 
MS (70 eV): m/z (%) 356 (100) [M+], 291 (15), 248 (88), 219 (25), 165 
(27), 89 (21). 
1,3-Dimethyl-5-ferrocenyl-4-phenylimidazolium iodide (5a): 
Compound 4a (70 mg, 0.20 mmol) was dissolved in acetonitrile (25 mL) 
and iodomethane (3 mL) was added. The reaction mixture was stirred at 
85 °C for 24 h. The solvent was evaporated and the residue was dried in 
vacuum. Yield: 97 mg (0.20 mmol, 100%); yellow gum; 1H NMR (300 
MHz, CDCl3) !=3.6–4.3 (m, 15H), 7.2–7.5 (m, 5H), 9.84 (s, 1H); 13C NMR 
(75.5 MHz, CDCl3) !=34.7, 35.8, 68.3, 68.7, 69.4, 125.5, 128.7, 128.9, 
130.4, 136.9; "max/cm-1: 3460, 3146, 3020, 1621, 1573, 1489, 1440, 1409, 
1343, 1202, 1105, 1086, 1058, 1004, 918, 893, 817, 763, 725, 703; MS 
(70 eV): m/z (%)  357 (92) [M+], 342 (100), 277 (34), 234 (49), 142 (52), 
121 (14). 
    
 
 
 
 
 
1,3-Diethyl-5-ferrocenyl-4-phenylimidazolium iodide (5b): Compound 
4b (100 mg, 0.28 mmol) was dissolved in acetonitrile (25 mL) and 
iodoethane (1.5 mL) was added. The reaction mixture was stirred at 
85 °C for 24 h. The solvent was evaporated and the residue was dried in 
vacuum. Yield: 130 mg (0.25 mmol, 89%); yellow gum; 1H NMR (300 
MHz, CDCl3) !=1.31 (t, J = 7.2 Hz, 3H), 1.63 (t, J = 7.2 Hz, 3H), 3.7–3.8 
(m, 5H), 4.0–4.1 (m, 4H), 4.1–4.2 (m, 2H), 4.56 (q, J = 7.2 Hz, 2H), 7.2–
7.5 (m, 5H), 10.01 (s, 1H); 13C NMR (75.5 MHz, CDCl3) !=15.3, 15.9, 
42.9, 43.1, 68.5, 59.2, 69.3, 69.5, 124.3, 125.5, 128.8, 129.0, 129.8, 
129.9, 130.2, 130.3, 130.4, 130.7, 134.9, 138.0; "max/cm-1: 3050, 2979, 
1936, 1617, 1561, 1444, 1410, 1386, 1342, 1220, 1182, 1105, 1090, 
1074, 1024, 1002, 918, 883, 819, 757, 724, 701, 639; MS (70 eV): m/z 
(%) 356 (100), 291 (10), 248 (15). 
Iodido-(1,3-dimethyl-4-ferrocenyl-5-phenylimidazol-2-ylidene)-
silver(I) (6a): A mixture of imidazolium salt 5a (95 mg, 0.20 mmol), 
CH2Cl2 (15 mL), and silver(I) oxide (46 mg, 0.20 mmol) was stirred at 
room temperature in the dark for 1 d. The suspension was filtered over 
Celite and the filtrate was concentrated in vacuum. The residue was 
dissolved in CH2Cl2 and the product precipitated with n-hexane. Yield: 72 
mg (0.12 mmol, 61%); brown gum; 1H NMR (300 MHz, CDCl3) !=3.55 (s, 
6H), 3.9–4.3 (m, 9H), 7.2–7.5 (m, 5H); 13C NMR (75.5 MHz, CDCl3) 
!=37.4, 38.2, 68.2, 68.8, 69.3, 72.9, 128.7, 128.9, 129.5, 130.3, 130.8, 
131.3, 179.8; "max/cm-1: 3085, 2947, 1622, 1595, 1574, 1503, 1445, 1377, 
1254, 1222, 1105, 1077, 1060, 1034, 1015, 911, 896, 820, 764, 723, 
700; MS (70 eV): m/z (%) 342 (45), 234 (38), 186 (99), 121 (91), 57 (38). 
Iodido-(1,3-diethyl-4-ferrocenyl-5-phenylimidazol-2-ylidene)silver(I) 
(6b): Analogously to 6a, compound 6b (90 mg, 0.15 mmol, 60%) was 
obtained from 5b (130 mg, 0.25 mmol), CH2Cl2 (15 mL), and silver(I) 
oxide (65 mg, 0.28 mmol) as a brown gum; 1H NMR (300 MHz, CDCl3) 
!=1.13 (t, J = 7.2 Hz, 3H), 1.47 (t, J = 7.2 Hz, 3H), 3.8–3.9 (m, 7H), 3.9–
4.0 (m, 2H), 4.1–4.2 (m, 2H), 4.48 (q, J = 7.2 Hz, 2H), 7.2–7.3 (m, 3H), 
7.4–7.5 (m, 2H); 13C NMR (75.5 MHz, CDCl3) !=17.2, 18.1, 44.5, 44.7, 
68.2, 68.7, 69.1, 72.8, 127.7, 128.3, 128.6, 128.8, 129.5, 130.2, 131.5, 
133.8, 177.8; "max/cm-1: 3084, 2970, 2928, 2865, 1499, 1459, 1443, 1398, 
1375, 1343, 1306, 1254, 1212, 1105, 1094, 1072, 1049, 1026, 1001, 965, 
919, 883, 821, 799, 757, 728, 701; MS (70 eV): m/z (%) 620 (1) [M+], 618 
(1) [M+], 528 (2), 526 (2), 383 (71), 356 (68), 275 (100), 247 (59), 219 
(16), 186 (20), 165 (18). 
Chlorido-(1,3-dimethyl-4-ferrocenyl-5-phenylimidazol-2-
ylidene)gold(I) (7a): Complex 6a (70 mg, 0.12 mmol) was dissolved in 
CH2Cl2 (15 mL) and treated with chloro(dimethylsulfide)gold(I) (49 mg, 
0.16 mmol). The reaction mixture was stirred at room temperature for 18 
h. The suspension was filtered, the filtrate was concentrated in vacuum 
and the residue recrystallised from CH2Cl2/n-hexane. Yield: 60 mg (0.10 
mmol, 86%); amber solid of m.p. 120 °C; 1H NMR (500 MHz, CD2Cl2) 
!=3.59 (s, 3H), 4.05 (s, 5H), 4.10 (m, 2H), 4.16 (s, 3H), 4.25 (m, 2H), 
7.28 (m, 2H), 7.51 (m, 3H); 13C NMR (125 MHz, CD2Cl2) !=38.1, 68.9, 
69.5, 69.9, 129,4, 129.6, 130.2, 131.6, 170.7; "max/cm-1: 3087, 2948, 
1621, 1595, 1575, 1445, 1382, 1266, 1218, 1121, 1106, 1081, 1058, 
1004, 927, 898, 821, 767, 701, 671; MS (70 eV): m/z (%) 588 (65) [M+], 
480 (54), 455 (100), 342 (79), 186 (100), 121 (40), 66 (57), 57 (36); 
elemental analysis calcd (%) for C21H20AuClFeN2 (588.66): C 43.85, H 
3.42, N 4.76; found: C 43.89, H 4.01, N 5.20. 
Chlorido-(1,3-diethyl-4-ferrocenyl-5-phenylimidazol-2-ylidene)gold(I) 
(7b): Analogously to 7a complex 7b (60 mg, 0.097 mmol, 81%) was 
obtained from 6b (75 mg, 0.12 mmol), CH2Cl2 (15 mL), and 
chloro(dimethylsulfide)gold(I) (36 mg, 0.12 mmol) as an amber solid of 
m.p. 85–87 °C; 1H NMR (500 MHz, CDCl3) !=1.22 (t, J = 7.2 Hz, 3H), 
1.58 (t, J = 7.2 Hz, 3H), 3.99 (s, 5H), 4.08 (m, 4H), 4.22 (m, 2H), 4.67 (m, 
2H), 7.33 (m, 2H), 7.49 (m, 3H); 13C NMR (75.5 MHz, CDCl3) !=16.8, 
17.6, 44.1, 44.2, 68.4, 69.0, 69.5, 69.7, 72.7, 127.9, 128.5, 128.8, 129.1, 
129.4, 129.8, 129.9, 130.4, 131.1, 133.8, 169.2; "max/cm-1: 2964, 2932, 
1623, 1593, 1504, 1461, 1444, 1409, 1377, 1345, 1308, 1262, 1214, 
1106, 1094, 1026, 1000, 967, 919, 885, 822, 758, 727, 702; MS (70 eV): 
m/z (%) 618 (18) [M+], 616 (47) [M+], 508 (52), 471 (45), 275 (51), 66 
(100); elemental analysis calcd (%) for C23H24AuClFeN2 (616.71): C 
44.79, H 3.92, N 4.54; found: C 45.09, H 3.93, N 4.79. 
Triphenylphosphino-(1,3-diethyl-4-ferrocenyl-5-phenylimidazol-2-
ylidene)gold(I) tetrafluoroborate (8): Complex 7b (45 mg, 0.073 mmol) 
was dissolved in acetone (10 mL) and treated with NaBF4 (15 mg, 0.136 
mmol) and PPh3 (25 mg, 0.095 mmol). The reaction mixture was stirred 
at room temperature for 1 h. The suspension was filtered, the filtrate was 
concentrated in vacuum and the residue recrystallised from CH2Cl2/n-
hexane. Yield: 50 mg (0.054 mmol, 74%); amber solid of m.p. 183 °C 
(dec.); 1H NMR (500 MHz, CDCl3) !=1.33 (dt, J = 14.6, 7.2 Hz, 3H), 1.70 
(dt, J = 14.6, 7.2 Hz, 3H), 4.04 (s, 5H), 4.13 (m, 4H), 4.28 (m, 2H), 4.73 
(m, 2H), 7.37 (m, 3H), 7.58 (m, 17H); 13C NMR (125 MHz, CDCl3) !=17.4, 
18.3, 18.4, 44.2, 44.5, 68.5, 68.6 69.1, 69.5, 72.0, 72.5, 128.2, 128.6, 
129.2, 129.3, 129.5, 129.8, 129.9, 130.0, 130.1, 130.6, 131.2, 132.4, 
133.8, 134.1, 134.2, 182.8; 31P NMR (202 MHz, CDCl3) ! 41.0; 11B NMR 
(96.3 MHz, CDCl3) != –1.18; "max/cm-1: 3059, 2963, 1480, 1464, 1436, 
1413, 1379, 1344, 1306, 1183, 1159, 1098, 1049, 997, 925, 884, 823, 
748, 693; MS (70 eV): m/z (%) 843.3 (100) [M+ -BF4], 735.4 (15), 721.3 
(49), 385.3 (24), 338 (16), 279 (13); elemental analysis calcd (%) for 
C41H39AuBF4FeN2P (930.35): C 52.93, H 4.23, N 3.01; found: C 53.10, H 
4.50, N 3.36. 
1,3-Diethyl-4-ferrocenyl-5-phenylimidazolium tetrafluoroborate (9): A 
mixture of 5b (67 mg, 0.13 mmol), acetone (30 mL), and NaBF4 (22 mg, 
0.20 mmol) was stirred at room temperature for 24 h. The mixture was 
filtered over MgSO4, the filtrate was concentrated in vacuum and the 
residue was dried. Yield: 60 mg (0.13 mmol, 100%); yellow gum; 1H NMR 
(300 MHz, CDCl3) !=1.40 (t, J = 7.3 Hz, 3H), 1.72 (t, J = 7.3 Hz, 3H), 
3.9–4.0 (m, 5H,), 4.0–4.1 (m, 4H), 4.3–4.4 (m, 2H), 4.66 (q, J = 7.3 Hz, 
2H), 7.3–7.4 (m, 2H), 7.5–7.7 (m, 3H), 10.18 (s, 1H); 13C NMR (75.5 MHz, 
CDCl3) !=15.6, 16.3, 44.3, 44.4, 68.8, 69.2, 69.6, 69.9, 70.2, 126.0, 
129.2, 129.4, 129.7, 130.1, 130.2, 130.5, 130.6, 130.8, 131.0, 135.5, 
148.5; "max/cm-1: 3055, 2978, 2936, 1615, 1561, 1444, 1410, 1386, 1342, 
1220, 1181, 1105, 1024, 1002, 918, 883, 819, 794, 757, 725, 702; MS(70 
eV): m/z (%) 356 (100), 291 (15), 248 (22). 
Bis-[1,3-diethyl-4-ferrocenyl-5-phenylimidazol-2-ylidene]gold(I) 
tetrafluoroborate (10): Imidazolium salt 9 (60 mg, 0.13 mmol) was 
dissolved in CH2Cl2/methanol (1:1, 30 mL) and treated with Ag2O (34 mg, 
0.14 mmol). The resulting mixture was stirred in the dark at room 
temperature for 5 h. Chloro(dimethylsulfide)gold(I) (23 mg, 0.075 mmol) 
was added and stirring was continued for a further 20 h. The suspension 
was filtered, the filtrate was concentrated in vacuum, and the residue was 
redissolved in CH2Cl2, and filtered over MgSO4/celite. The filtrate was 
concentrated and the remainder was dried in vacuum. Yield: 50 mg (0.05 
mmol, 64%); amber solid of m.p. 183 °C (dec.); 1H NMR (300 MHz, 
CDCl3) !=1.1–1.3 (m, 6H), 1.6–1.8 (m, 6H), 3.8–4.3 (m, 22H), 4.6–4.8 (m, 
4H), 7.1–7.6 (m, 10H); 13C NMR (75.5 MHz, CDCl3) !=16.8, 17.3, 17.6, 
18.2, 44.1, 44.2, 68.5, 69.0, 69.1, 69.3, 69.4, 72.4, 72.8, 128.0, 128.5, 
128.9, 129.1, 129.4, 129.8, 130.5, 130.8, 131.2, 131.8, 135.0, 161.2, 
182.7; 11B NMR (96.3 MHz, CDCl3) != –1.29; "max/cm-1: 2972, 2924, 
1462, 1446, 1411, 1378, 1345, 1306, 1262, 1216, 1195, 1107, 1050, 
1002, 969, 885, 834, 818, 757, 703; MS (70 eV): m/z (%) 965.2 (100) [M+ 
–BF4], 857.4 (6), 506.8 (7), 338.5 (23), 282.4 (7); elemental analysis 
calcd (%) for C46H48AuBF4Fe2N4 (1052.36): C 52.50, H 4.60, N 5.32; 
found: C 52.48, H 4.55, N 5.02.  
Crystal data: C46H48AuBF4Fe2N4, M=1052.36, monoclinic, space group 
C2/c, a=19.657(4), b=10.889(2), c=21.868(4) Å, !="=90°, #=114.33(3)°, 
V=4264.8(15) Å3, Z=4, $=0.71073 Å, #=4.158 mm–1, T=293(2) K; 15540 
reflections measured, 4121 unique; final refinement to convergence on 
F
2 gave R=0.0539 and Rw=0.1161, GOF=0.703. CCDC 1500972.  
Biological Studies. Enzyme: PARP-1 activity was determined using 
Trevigen’s HT universal colorimetric PARP assay according to the 
    
 
 
 
 
 
manufacturer’s instructions. It measures the incorporation of biotinylated 
poly(ADP-ribose) in histone proteins in a 96-microtiter strip well format. 
Recombinant human PARP-1 (high specific activity, purified from E. coli 
containing recombinant plasmid harboring the human PARP gene) was 
used as the enzyme source and incubated with different concentrations 
of complexes 8 and 10 for 1 h at room temperature prior to its addition to 
the histone proteins in the 96-well plates. The final reaction mixture (50 
µL) was treated with TACS-Sapphire, a horseradish peroxidase 
colorimetric substrate, and incubated in the dark for 30 min. The 
absorbance was measured at 630 nm. The experiment was performed 
twice in duplicate and EC50 values are presented as means ± S.D..  
The inhibition of thioredoxin reductase (TrxR) by 8 and 10 was assessed 
using a microplate reader based assay with minor modifications.[4,38,61] 
Rat liver TrxR (Sigma-Aldrich) was diluted with water to a concentration 
of 2.0 U/mL. To 25 µL aliquots of the enzyme solution 25 µL of potassium 
phosphate buffer pH 7.0 containing the complexes 8 and 10 in graded 
concentrations or vehicle (DMF) were added. The resulting solutions 
(final concentration of DMF: 0.5% v/v) were incubated for 75 min at 37 °C 
in a 96-well plate. To each well, 225 µL of the reaction mixture (1000 µL 
reaction mixture: 500 µL potassium phosphate buffer pH 7.0, 80 µL 100 
mM EDTA solution pH 7.5, 20 µL BSA solution 0.05%, 100 µL of 20mM 
NADPH solution, and 300 µL of distilled water) were added and the 
reaction was started by adding 25 µL of a 20 mM DTNB solution. The 
formation of 5-TNB was monitored with a Perkin-Elmer Victor X4 
microplate reader at 405 nm in 10 s intervals for 6 min. The increase in 5-
TNB concentrations over time followed a linear trend (r2 % 0.99), and the 
enzymatic activities were calculated as the slopes (increase in 
absorbance per second) thereof. The noninterference of the test 
compounds with the assay components was confirmed by negative 
control experiments with enzyme-free solution. The EC50 values are the 
complex concentrations decreasing the enzymatic activity to 50%, given 
as means ± S.D. of two or three experiments in duplicate. 
Tube Formation Assay: The interference of 8 and 10 with the formation 
of vascular-like tubular networks by HUVEC was investigated in vitro. 
HUVEC (25 !L of 8!105 cells/mL) were seeded on matrigel (BD 
Biosciences) in black 96-well plates and treated with 8 or 10 (dilution of 
10 mM stock solutions in DMF ranging from 50 nM to 10 µM in H2O) to 
identify antiangiogenic activity. Solvent controls (DMF) were treated 
identically. Effects were documented by light microscopy after 24 h of 
incubation (Axiovert 35, 5! objective lens, AxioCam color, Zeiss).[9,53,62] 
Chorioallantoic Membrane (CAM) Assay: Fertilized, specific pathogen-
free (SPF) chicken eggs (VALO BioMedia) were bred in an incubator at 
37 °C and 60% relative humidity. On day 6 windows (Ø 1.5–2 cm) were 
cut into the shell at the more rounded pole of the egg. The holes were 
sealed with tape, and incubation was continued overnight. Rings of 
silicon foil (Ø 5 mm) were placed on the CAM with its developing blood 
vessels, and complexes 8 or 10 (2.5 nmol), or DMF as control (all in a 
volume of 10 !L H2O) were topically applied within the rings. The effects 
on the developing vasculature were documented after incubation for 6 h 
and 24 h using a light microscope (60! magnification, Traveler). The 
fractal analyses to quantify a decrease in areas covered by blood vessels 
after 6 h of incubation with the test compounds was carried out as 
described before using ImageJ 1.48f (FracLac_2015Jul plugin) and the 
Fractal Analysis System 3.4.7 software.[9]  
Mouse Xenograft Model: The animal studies had been approved by the 
committee on animal care (Government of Rhineland–Palatinate). The 
mice (Balb/c) were kept under a 12 h light–dark cycle in a controlled 
conventional colony room. They had free access to sterilized water and 
standard rodent diet ad libitum. They were sacrificed by cervical 
dislocation corresponding to the guidelines of the committee on animal 
care. To analyze the in vivo antitumor activity and tolerance of gold 
complex 10, a Balb/c mouse xenograft model of highly metastatic B16-
F10 mouse melanoma cells was used. A suspension of 2 ! 105 cells in 
200 mL PBS was administered to the flanks of each mouse to generate 
subcutaneous xenograft tumors. Freshly prepared 9 mM stock solutions 
of complex 10 in DMSO were diluted 1:9 with PBS and injected i.p. twice 
on two consecutive days (days 1, 2, and 7, 8) in the mice (n=3) at 7.5 mg 
! (kg body weight)-1. Control mice (n=3) were treated with respective 
amounts of DMSO (in PBS). The size of the tumors was recorded daily, 
beginning on the day of the first injection. Tumor volumes were 
calculated by the formula a2 ! b ! 0.5, with a being the short and b the 
long dimension. The weight of the mice was measured at the beginning 
(day 1) and at the end of the experiment (day 12) and was used as an 
indication of drug tolerance.  
Further tests: For details on the studies of growth inhibition, cellular 
accumulation, partition coefficients, interference with F-actin and 
mitochondrial membrane potential, cell cycle, wound healing, and ROS 
generation refer to the Supporting information.  
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